Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs First Citizens BancShares Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.06 (market cap $39.89B), while First Citizens BancShares Inc trades at $2,105 (market cap $23.94B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FCNCA | |
|---|---|---|
Market Cap | $39.89B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $2.20K |
52-Week Low | $278.09 | $1.64K |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $288.06, down 3.58% today, with a bullish technical signal supported by oscillators and strong institutional sentiment. The company reported robust revenue growth to $3.71B in 2025, turning profitable with net income of $313.75M, and shows a positive earnings beat trend. Recent news highlights pipeline advancements and strategic AI partnerships aimed at accelerating drug discovery.
Outlook remains positive with a consensus price target of $414.40, implying 44% upside, driven by pipeline diversification and market expansion. Key risks include clinical trial outcomes and dependence on key drug Amvuttra. Wall Street maintains strong buy consensus (75% buy ratings) amid expectations for sustained growth and potential S&P 500 inclusion.
First Citizens BancShares (FCNCA) trades at $2,092.59, up 0.46% daily, with a bearish technical signal despite bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a solid net income margin of 24.35%. Recent news highlights expansion in commercial banking and a planned rebrand of Silicon Valley Bank operations.
Outlook remains mixed with analyst consensus leaning hold (81.82%) amid margin pressure and credit risk concerns. The stock offers value with a P/E of 12.07 but faces headwinds from tech sector exposure and potential deposit volatility. Upside is capped near the consensus price target of $2,320.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
